PMID- 26848215
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160205
LR  - 20200930
IS  - 1013-9087 (Print)
IS  - 2005-3894 (Electronic)
IS  - 1013-9087 (Linking)
VI  - 28
IP  - 1
DP  - 2016 Feb
TI  - Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an 
      Oxazolone-Induced Atopic Dermatitis Model.
PG  - 22-9
LID - 10.5021/ad.2016.28.1.22 [doi]
AB  - BACKGROUND: Many inflammatory mediators, including various cytokines (e.g. 
      interleukins and tumor necrosis factor [TNF]), inflammatory proteases, and 
      histamine are released following mast cell activation. However, the endogenous 
      modulators for mast cell activation and the underlying mechanism have yet to be 
      elucidated. Endogenous cannabinoids such as palmitoylethanolamide (PEA) and 
      N-arachidonoylethanolamine (anandamide or AEA), were found in peripheral tissues 
      and have been proposed to possess autacoid activity, implying that cannabinoids 
      may downregulate mast cell activation and local inflammation. OBJECTIVE: In order 
      to investigate the effect of cannabinoid receptor-1 (CB1R) agonists on mast cell 
      activation, AEA-derived compounds were newly synthesized and evaluated for their 
      effect on mast cell activation. METHODS: The effects of selected compounds on 
      FcepsilonRI-induced histamine and beta-hexosaminidase release were evaluated in a rat 
      basophilic leukemia cell line (RBL-2H3). To further investigate the inhibitory 
      effects of CB1R agonist in vivo, an oxazolone-induced atopic dermatitis mouse 
      model was exploited. RESULTS: We found that CB1R inhibited the release of 
      inflammatory mediators without causing cytotoxicity in RBL-2H3 cells and that 
      CB1R agonists markedly and dose-dependently suppressed mast cell proliferation 
      indicating that CB1R plays an important role in modulating antigen-dependent 
      immunoglobulin E (IgE)-mediated mast cell activation. We also found that topical 
      application of CB1R agonists suppressed the recruitment of mast cells into the 
      skin and reduced the level of blood histamine. CONCLUSION: Our results indicate 
      that CB1R agonists down-regulate mast cell activation and may be used for 
      relieving inflammatory symptoms mediated by mast cell activation, such as atopic 
      dermatitis, psoriasis, and contact dermatitis.
FAU - Nam, Gaewon
AU  - Nam G
AD  - Department of Cosmetic Science and Technology, Seowon University, Cheongju, 
      Korea.
FAU - Jeong, Se Kyoo
AU  - Jeong SK
AD  - CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
FAU - Park, Bu Man
AU  - Park BM
AD  - CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
FAU - Lee, Sin Hee
AU  - Lee SH
AD  - CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
FAU - Kim, Hyun Jong
AU  - Kim HJ
AD  - Department of Dermatology, Atopy and Asthma Center and Seoul Medical Research 
      Institute, Seoul Medical Center, Seoul, Korea.
FAU - Hong, Seung-Phil
AU  - Hong SP
AD  - Department of Dermatology, Dankook University Medical College, Cheonan, Korea.
FAU - Kim, Beomjoon
AU  - Kim B
AD  - Department of Dermatology, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Kim, Bong-Woo
AU  - Kim BW
AD  - Department of Cosmetic Science and Technology, Seowon University, Cheongju, 
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20160128
PL  - Korea (South)
TA  - Ann Dermatol
JT  - Annals of dermatology
JID - 8916577
PMC - PMC4737832
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Cannabinoid receptor agonists
OT  - Histamine
OT  - Mast cells
EDAT- 2016/02/06 06:00
MHDA- 2016/02/06 06:01
PMCR- 2016/02/01
CRDT- 2016/02/06 06:00
PHST- 2015/02/02 00:00 [received]
PHST- 2015/05/03 00:00 [revised]
PHST- 2015/05/06 00:00 [accepted]
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2016/02/06 06:01 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.5021/ad.2016.28.1.22 [doi]
PST - ppublish
SO  - Ann Dermatol. 2016 Feb;28(1):22-9. doi: 10.5021/ad.2016.28.1.22. Epub 2016 Jan 
      28.